Targeted therapies of gastrointestinal stromal tumors (GIST)-The next frontiers

Biochemical Pharmacology

Volumn 80, Issue 5, 2010, Pages 575-583

  Duensing, Stefan ^a,b   Duensing, Anette ^a,b  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Gastrointestinal stromal tumors; Kinase; KIT; Small molecular inhibitor; Targeted therapy

Indexed keywords

1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; 2 (1H INDAZOL 4 YL) 6 (4 METHANESULFONYL 1 PIPERAZINYLMETHYL) 4 MORPHOLINOTHIENO[3,2 D]PYRIMIDINE; [1 (4 OXO 8 PHENYL 4H 1 BENZOPYRAN 2 YL)MORPHOLINIO]METHOXYSUCCINYLARGINYLGLYCYLASPARTYLSERINE ACETATE; AFINITOR; ANTINEOPLASTIC AGENT; BORTEZOMIB; DASATINIB; EVEROLIMUS; GDC 0973; GELDANAMYCIN; IMATINIB; NILOTINIB; PANOBINOSTAT; PERIFOSINE; PF 04691502; PLACEBO; PLATELET DERIVED GROWTH FACTOR RECEPTOR; RAPAMYCIN; RDEA 119; SORAFENIB; STA 9090; STEM CELL FACTOR RECEPTOR; SU 112448; SUNITINIB; TANESPIMYCIN; TANESPIMYCIN HYDROQUINONE; TEMSIROLIMUS; TRICHOSTATIN A; UNCLASSIFIED DRUG; VALPROIC ACID; VORINOSTAT; XL 281; XL 418; XL 518; XL 765;

APOPTOSIS; CELL CYCLE; CELL DEATH; CELL DIVISION; CELL SURVIVAL; DRUG ACTIVITY; GASTROINTESTINAL STROMAL TUMOR; GENE MUTATION; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; GASTROINTESTINAL STROMAL TUMORS; HUMANS; PIPERAZINES; PROTO-ONCOGENE PROTEINS C-KIT; PYRIMIDINES; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA;

EID: 77954213847     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2010.04.006     Document Type: Review

References (150)

1. Duensing A., Heinrich M.C., Fletcher C.D., Fletcher J.A. Biology of gastrointestinal stromal tumors: KIT mutations and beyond. Cancer Invest 2004, 22(1):106-116.
2. Liegl-Atzwanger B., Fletcher J.A., Fletcher C.D. Gastrointestinal stromal tumors. Virchows Arch 2010, 456(2):111-127.
3. Isozaki K., Hirota S., Miyagawa J., Taniguchi M., Shinomura Y., Matsuzawa Y. Deficiency of c-kit+ cells in patients with a myopathic form of chronic idiopathic intestinal pseudo-obstruction. Am J Gastroenterol 1997, 92(2):332-334.
4. Isozaki K., Hirota S., Nakama A., Miyagawa J., Shinomura Y., Xu Z., et al. Disturbed intestinal movement, bile reflux to the stomach, and deficiency of c-kit-expressing cells in Ws/Ws mutant rats. Gastroenterology 1995, 109(2):456-464.
5. Hirota S., Isozaki K., Moriyama Y., Hashimoto K., Nishida T., Ishiguro S., et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998, 279(5350):577-580.
6. Kindblom L.G., Remotti H.E., Aldenborg F., Meis-Kindblom J.M. Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. Am J Pathol 1998, 152(5):1259-1269.
7. Heinrich M.C., Corless C.L., Duensing A., McGreevey L., Chen C.J., Joseph N., et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science 2003, 299(5607):708-710.
8. Hirota S., Ohashi A., Nishida T., Isozaki K., Kinoshita K., Shinomura Y., et al. Gain-of-function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumors. Gastroenterology 2003, 125(3):660-667.
9. Medeiros F., Corless C.L., Duensing A., Hornick J.L., Oliveira A.M., Heinrich M.C., et al. KIT-negative gastrointestinal stromal tumors: proof of concept and therapeutic implications. Am J Surg Pathol 2004, 28(7):889-894.
10. Debiec-Rychter M., Wasag B., Stul M., De Wever I., Van Oosterom A., Hagemeijer A., et al. Gastrointestinal stromal tumours (GISTs) negative for KIT (CD117 antigen) immunoreactivity. J Pathol 2004, 202(4):430-438.
11. Miettinen M., Lasota J., Sobin L.H. Gastrointestinal stromal tumors of the stomach in children and young adults: a clinicopathologic, immunohistochemical, and molecular genetic study of 44 cases with long-term follow-up and review of the literature. Am J Surg Pathol 2005, 29(10):1373-1381.
12. Kontogianni-Katsarou K., Lariou C., Tsompanaki E., Vourlakou C., Kairi-Vassilatou E., Mastoris C., et al. KIT-negative gastrointestinal stromal tumors with a long term follow-up: a new subgroup does exist. World J Gastroenterol 2007, 13(7):1098-1102.
13. Nielsen T.O., West R.B., Linn S.C., Alter O., Knowling M.A., O'Connell J.X., et al. Molecular characterisation of soft tissue tumours: a gene expression study. Lancet 2002, 359(9314):1301-1307.
14. Allander S.V., Nupponen N.N., Ringner M., Hostetter G., Maher G.W., Goldberger N., et al. Gastrointestinal stromal tumors with KIT mutations exhibit a remarkably homogeneous gene expression profile. Cancer Res 2001, 61(24):8624-8628.
15. Duensing A., Joseph N.E., Medeiros F., Smith F., Hornick J.L., Heinrich M.C., et al. Protein Kinase C theta (PKCtheta) expression and constitutive activation in gastrointestinal stromal tumors (GISTs). Cancer Res 2004, 64(15):5127-5131.
16. Lee H.E., Kim M.A., Lee H.S., Lee B.L., Kim W.H. Characteristics of KIT-negative gastrointestinal stromal tumours and diagnostic utility of protein kinase C theta immunostaining. J Clin Pathol 2008, 61(6):722-729.
17. Blay P., Astudillo A., Buesa J.M., Campo E., Abad M., Garcia-Garcia J., et al. Protein kinase C theta is highly expressed in gastrointestinal stromal tumors but not in other mesenchymal neoplasias. Clin Cancer Res 2004, 10(12 Pt 1):4089-4095.
18. Motegi A., Sakurai S., Nakayama H., Sano T., Oyama T., Nakajima T. PKC theta, a novel immunohistochemical marker for gastrointestinal stromal tumors (GIST), especially useful for identifying KIT-negative tumors. Pathol Int 2005, 55(3):106-112.
19. West R.B., Corless C.L., Chen X., Rubin B.P., Subramanian S., Montgomery K., et al. The novel marker, DOG1, is expressed ubiquitously in gastrointestinal stromal tumors irrespective of KIT or PDGFRA mutation status. Am J Pathol 2004, 165(1):107-113.
20. Espinosa I., Lee C.H., Kim M.K., Rouse B.T., Subramanian S., Montgomery K., et al. A novel monoclonal antibody against DOG1 is a sensitive and specific marker for gastrointestinal stromal tumors. Am J Surg Pathol 2008, 32(2):210-218.
21. Miettinen M., Wang Z.F., Lasota J. DOG1 antibody in the differential diagnosis of gastrointestinal stromal tumors: a study of 1840 cases. Am J Surg Pathol 2009, 33(9):1401-1408.
22. Qiu F.H., Ray P., Brown K., Barker P.E., Jhanwar S., Ruddle F.H., et al. Primary structure of c-kit: relationship with the CSF-1/PDGF receptor kinase family-oncogenic activation of v-kit involves deletion of extracellular domain and C terminus. EMBO J 1988, 7(4):1003-1011.
23. Besmer P., Murphy J.E., George P.C., Qiu F.H., Bergold P.J., Lederman L., et al. A new acute transforming feline retrovirus and relationship of its oncogene v-kit with the protein kinase gene family. Nature 1986, 320(6061):415-421.
24. Chabot B., Stephenson D.A., Chapman V.M., Besmer P., Bernstein A. The proto-oncogene c-kit encoding a transmembrane tyrosine kinase receptor maps to the mouse W locus. Nature 1988, 335(6185):88-89.
25. Majumder S., Brown K., Qiu F.H., Besmer P. c-kit protein, a transmembrane kinase: identification in tissues and characterization. Mol Cell Biol 1988, 8(11):4896-4903.
26. Nocka K., Buck J., Levi E., Besmer P. Candidate ligand for the c-kit transmembrane kinase receptor: KL, a fibroblast derived growth factor stimulates mast cells and erythroid progenitors. EMBO J 1990, 9(10):3287-3294.
27. Mol C.D., Dougan D.R., Schneider T.R., Skene R.J., Kraus M.L., Scheibe D.N., et al. Structural basis for the autoinhibition and STI-571 inhibition of c-Kit tyrosine kinase. J Biol Chem 2004, 279(30):31655-31663.
28. Mol C.D., Lim K.B., Sridhar V., Zou H., Chien E.Y., Sang B.C., et al. Structure of a c-kit product complex reveals the basis for kinase transactivation. J Biol Chem 2003, 278(34):31461-31464.
29. Duensing A., Medeiros F., McConarty B., Joseph N.E., Panigrahy D., Singer S., et al. Mechanisms of oncogenic KIT signal transduction in primary gastrointestinal stromal tumors (GISTs). Oncogene 2004, 23(22):3999-4006.
30. Tsujimura T., Hashimoto K., Kitayama H., Ikeda H., Sugahara H., Matsumura I., et al. Activating mutation in the catalytic domain of c-kit elicits hematopoietic transformation by receptor self-association not at the ligand-induced dimerization site. Blood 1999, 93(4):1319-1329.
31. Rubin B.P., Singer S., Tsao C., Duensing A., Lux M.L., Ruiz R., et al. KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res 2001, 61(22):8118-8121.
32. Gramza A.W., Corless C.L., Heinrich M.C. Resistance to tyrosine kinase inhibitors in gastrointestinal stromal tumors. Clin Cancer Res 2009, 15(24):7510-7518.
33. Lasota J., Wozniak A., Sarlomo-Rikala M., Rys J., Kordek R., Nassar A., et al. Mutations in exons 9 and 13 of KIT gene are rare events in gastrointestinal stromal tumors. A study of 200 cases. Am J Pathol 2000, 157(4):1091-1095.
34. Antonescu C.R., Sommer G., Sarran L., Tschernyavsky S.J., Riedel E., Woodruff J.M., et al. Association of KIT exon 9 mutations with nongastric primary site and aggressive behavior: KIT mutation analysis and clinical correlates of 120 gastrointestinal stromal tumors. Clin Cancer Res 2003, 9(9):3329-3337.
35. Antonescu C.R., Viale A., Sarran L., Tschernyavsky S.J., Gonen M., Segal N.H., et al. Gene expression in gastrointestinal stromal tumors is distinguished by KIT genotype and anatomic site. Clin Cancer Res 2004, 10(10):3282-3290.
36. Lasota J., Dansonka-Mieszkowska A., Stachura T., Schneider-Stock R., Kallajoki M., Steigen S.E., et al. Gastrointestinal stromal tumors with internal tandem duplications in 3' end of KIT juxtamembrane domain occur predominantly in stomach and generally seem to have a favorable course. Mod Pathol 2003, 16(12):1257-1264.
37. Wardelmann E., Neidt I., Bierhoff E., Speidel N., Manegold C., Fischer H.P., et al. c-kit mutations in gastrointestinal stromal tumors occur preferentially in the spindle rather than in the epithelioid cell variant. Mod Pathol 2002, 15(2):125-136.
38. Debiec-Rychter M., Lasota J., Sarlomo-Rikala M., Kordek R., Miettinen M. Chromosomal aberrations in malignant gastrointestinal stromal tumors: correlation with c-KIT gene mutation. Cancer Genet Cytogenet 2001, 128(1):24-30.
39. Lasota J., Dansonka-Mieszkowska A., Sobin L.H., Miettinen M. A great majority of GISTs with PDGFRA mutations represent gastric tumors of low or no malignant potential. Lab Invest 2004, 84(7):874-883.
40. Wardelmann E., Hrychyk A., Merkelbach-Bruse S., Pauls K., Goldstein J., Hohenberger P., et al. Association of platelet-derived growth factor receptor alpha mutations with gastric primary site and epithelioid or mixed cell morphology in gastrointestinal stromal tumors. J Mol Diagn 2004, 6(3):197-204.
41. Corless C.L., McGreevey L., Haley A., Town A., Heinrich M.C. KIT mutations are common in incidental gastrointestinal stromal tumors one centimeter or less in size. Am J Pathol 2002, 160(5):1567-1572.
42. Kawanowa K., Sakuma Y., Sakurai S., Hishima T., Iwasaki Y., Saito K., et al. High incidence of microscopic gastrointestinal stromal tumors in the stomach. Hum Pathol 2006, 37(12):1527-1535.
43. Agaimy A., Wunsch P.H., Hofstaedter F., Blaszyk H., Rummele P., Gaumann A., et al. Minute gastric sclerosing stromal tumors (GIST tumorlets) are common in adults and frequently show c-KIT mutations. Am J Surg Pathol 2007, 31(1):113-120.
44. Chetty R. Small and microscopically detected gastrointestinal stromal tumours: an overview. Pathology 2008, 40(1):9-12.
45. Heinrich M.C., Griffith D.J., Druker B.J., Wait C.L., Ott K.A., Zigler A.J. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood 2000, 96(3):925-932.
46. Tuveson D.A., Willis N.A., Jacks T., Griffin J.D., Singer S., Fletcher C.D., et al. STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications. Oncogene 2001, 20(36):5054-5058.
47. McWhinney S.R., Pasini B., Stratakis C.A. Familial gastrointestinal stromal tumors and germ-line mutations. N Engl J Med 2007, 357(10):1054-1056.
48. Li F.P., Fletcher J.A., Heinrich M.C., Garber J.E., Sallan S.E., Curiel-Lewandrowski C., et al. Familial gastrointestinal stromal tumor syndrome: phenotypic and molecular features in a kindred. J Clin Oncol 2005, 23(12):2735-2743.
49. O'Riain C., Corless C.L., Heinrich M.C., Keegan D., Vioreanu M., Maguire D., et al. Gastrointestinal stromal tumors: insights from a new familial GIST kindred with unusual genetic and pathologic features. Am J Surg Pathol 2005, 29(12):1680-1683.
50. Chompret A., Kannengiesser C., Barrois M., Terrier P., Dahan P., Tursz T., et al. PDGFRA germline mutation in a family with multiple cases of gastrointestinal stromal tumor. Gastroenterology 2004, 126(1):318-321.
51. Beghini A., Tibiletti M.G., Roversi G., Chiaravalli A.M., Serio G., Capella C., et al. Germline mutation in the juxtamembrane domain of the kit gene in a family with gastrointestinal stromal tumors and urticaria pigmentosa. Cancer 2001, 92(3):657-662.
52. Hirota S., Nishida T., Isozaki K., Taniguchi M., Nishikawa K., Ohashi A., et al. Familial gastrointestinal stromal tumors associated with dysphagia and novel type germline mutation of KIT gene. Gastroenterology 2002, 122(5):1493-1499.
53. Isozaki K., Terris B., Belghiti J., Schiffmann S., Hirota S., Vanderwinden J.M. Germline-activating mutation in the kinase domain of KIT gene in familial gastrointestinal stromal tumors. Am J Pathol 2000, 157(5):1581-1585.
54. Maeyama H., Hidaka E., Ota H., Minami S., Kajiyama M., Kuraishi A., et al. Familial gastrointestinal stromal tumor with hyperpigmentation: association with a germline mutation of the c-kit gene. Gastroenterology 2001, 120(1):210-215.
55. Nishida T., Hirota S., Taniguchi M., Hashimoto K., Isozaki K., Nakamura H., et al. Familial gastrointestinal stromal tumours with germline mutation of the KIT gene. Nat Genet 1998, 19(4):323-324.
56. Sommer G., Agosti V., Ehlers I., Rossi F., Corbacioglu S., Farkas J., et al. Gastrointestinal stromal tumors in a mouse model by targeted mutation of the Kit receptor tyrosine kinase. Proc Natl Acad Sci USA 2003, 100(11):6706-6711.
57. Rubin B.P., Antonescu C.R., Scott-Browne J.P., Comstock M.L., Gu Y., Tanas M.R., et al. A knock-in mouse model of gastrointestinal stromal tumor harboring kit K641E. Cancer Res 2005, 65(15):6631-6639.
58. Nakai N., Ishikawa T., Nishitani A., Liu N.N., Shincho M., Hao H., et al. A mouse model of a human multiple GIST family with KIT-Asp820Tyr mutation generated by a knock-in strategy. J Pathol 2008, 214(3):302-311.
59. Janeway K.A., Liegl B., Harlow A., Le C., Perez-Atayde A., Kozakewich H., et al. Pediatric KIT wild-type and platelet-derived growth factor receptor alpha-wild-type gastrointestinal stromal tumors share KIT activation but not mechanisms of genetic progression with adult gastrointestinal stromal tumors. Cancer Res 2007, 67(19):9084-9088.
60. Tarn C., Rink L., Merkel E., Flieder D., Pathak H., Koumbi D., et al. Insulin-like growth factor 1 receptor is a potential therapeutic target for gastrointestinal stromal tumors. Proc Natl Acad Sci USA 2008, 105(24):8387-8392.
61. Agaram N.P., Laquaglia M.P., Ustun B., Guo T., Wong G.C., Socci N.D., et al. Molecular characterization of pediatric gastrointestinal stromal tumors. Clin Cancer Res 2008, 14(10):3204-3215.
62. Janeway KA, Zhu MJ, Barretina J, Perez-Atayde A, Demetri GD, Fletcher JA. Strong expression of IGF1R in pediatric gastrointestinal stromal tumors without IGF1R genomic amplification. Int J Cancer 2010; [Epub ahead of print].
63. Pasini B., Matyakhina L., Bei T., Muchow M., Boikos S., Ferrando B., et al. Multiple gastrointestinal stromal and other tumors caused by platelet-derived growth factor receptor alpha gene mutations: a case associated with a germline V561D defect. J Clin Endocrinol Metab 2007, 92(9):3728-3732.
64. Pasini B., McWhinney S.R., Bei T., Matyakhina L., Stergiopoulos S., Muchow M., et al. Clinical and molecular genetics of patients with the Carney-Stratakis syndrome and germline mutations of the genes coding for the succinate dehydrogenase subunits SDHB, SDHC, and SDHD. Eur J Hum Genet 2008, 16(1):79-88.
65. Janeway M.D., Katherine A., Liegl B., Nose V., Hornick J.L., Barretina J., et al. Complete loss of succinate dehydrogenase B (SDHB) protein in pediatric gastrointestinal stromal tumors (GIST). Annual Meeting, Connective Tissue Oncology Society 2009, [abstract 39408].
66. Agaram N.P., Wong G.C., Guo T., Maki R.G., Singer S., Dematteo R.P., et al. Novel V600E BRAF mutations in imatinib-naive and imatinib-resistant gastrointestinal stromal tumors. Genes Chromosomes Cancer 2008, 47(10):853-859.
67. Agaimy A., Terracciano L.M., Dirnhofer S., Tornillo L., Foerster A., Hartmann A., et al. V600E BRAF mutations are alternative early molecular events in a subset of KIT/PDGFRA wild-type gastrointestinal stromal tumours. J Clin Pathol 2009, 62(7):613-616.
68. Buchdunger E., Cioffi C.L., Law N., Stover D., Ohno-Jones S., Druker B.J., et al. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 2000, 295(1):139-145.
69. Demetri G.D., von Mehren M., Blanke C.D., Van den Abbeele A.D., Eisenberg B., Roberts P.J., et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002, 347(7):472-480.
70. Joensuu H., Roberts P.J., Sarlomo-Rikala M., Andersson L.C., Tervahartiala P., Tuveson D., et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 2001, 344(14):1052-1056.
71. van Oosterom A.T., Judson I.R., Verweij J., Stroobants S., Dumez H., Donato di Paola E., et al. Update of phase I study of imatinib (STI571) in advanced soft tissue sarcomas and gastrointestinal stromal tumors: a report of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 2002, 38(Suppl 5):S83-S87.
72. Blanke C.D., Rankin C., Demetri G.D., Ryan C.W., von Mehren M., Benjamin R.S., et al. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol 2008, 26(4):626-632.
73. Verweij J., Casali P.G., Zalcberg J., LeCesne A., Reichardt P., Blay J.Y., et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 2004, 364(9440):1127-1134.
74. Gold J.S., van der Zwan S.M., Gonen M., Maki R.G., Singer S., Brennan M.F., et al. Outcome of metastatic GIST in the era before tyrosine kinase inhibitors. Ann Surg Oncol 2007, 14(1):134-142.
75. Blanke C.D., Demetri G.D., von Mehren M., Heinrich M.C., Eisenberg B., Fletcher J.A., et al. Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol 2008, 26(4):620-625.
76. Debiec-Rychter M., Sciot R., Le Cesne A., Schlemmer M., Hohenberger P., van Oosterom A.T., et al. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer 2006, 42(8):1093-1103.
77. Heinrich M.C., Corless C.L., Demetri G.D., Blanke C.D., von Mehren M., Joensuu H., et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 2003, 21(23):4342-4349.
78. Debiec-Rychter M., Dumez H., Judson I., Wasag B., Verweij J., Brown M., et al. Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 2004, 40(5):689-695.
79. Heinrich M.C., Owzar K., Corless C.L., Hollis D., Borden E.C., Fletcher C.D., et al. Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group. J Clin Oncol 2008, 26(33):5360-5367.
80. Gastrointestinal Stromal Tumor Meta-Analysis Group (MetaGIST). Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: a meta-analysis of 1,640 patients. J Clin Oncol 2010;28(7):1247-53.
81. Corless C.L., Schroeder A., Griffith D., Town A., McGreevey L., Harrell P., et al. PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib. J Clin Oncol 2005, 23(23):5357-5364.
82. Weisberg E., Wright R.D., Jiang J., Ray A., Moreno D., Manley P.W., et al. Effects of PKC412, nilotinib, and imatinib against GIST-associated PDGFRA mutants with differential imatinib sensitivity. Gastroenterology 2006, 131(6):1734-1742.
83. Bauer S., Duensing A., Demetri G.D., Fletcher J.A. KIT oncogenic signaling mechanisms in imatinib-resistant gastrointestinal stromal tumor: PI3-kinase/AKT is a crucial survival pathway. Oncogene 2007, 26(54):7560-7568.
84. Liu Y., Tseng M., Perdreau S.A., Rossi F., Antonescu C., Besmer P., et al. Histone H2AX is a mediator of gastrointestinal stromal tumor cell apoptosis following treatment with imatinib mesylate. Cancer Res 2007, 67(6):2685-2692.
85. Rogakou E.P., Pilch D.R., Orr A.H., Ivanova V.S., Bonner W.M. DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139. J Biol Chem 1998, 273(10):5858-5868.
86. Rossi F., Ehlers I., Agosti V., Socci N.D., Viale A., Sommer G., et al. Oncogenic Kit signaling and therapeutic intervention in a mouse model of gastrointestinal stromal tumor. Proc Natl Acad Sci USA 2006.
87. Tarn C., Skorobogatko Y.V., Taguchi T., Eisenberg B., von Mehren M., Godwin A.K. Therapeutic effect of imatinib in gastrointestinal stromal tumors: AKT signaling dependent and independent mechanisms. Cancer Res 2006, 66(10):5477-5486.
88. Kuroda J., Puthalakath H., Cragg M.S., Kelly P.N., Bouillet P., Huang D.C., et al. Bim and Bad mediate imatinib-induced killing of Bcr/Abl+ leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic. Proc Natl Acad Sci USA 2006, 103(40):14907-14912.
89. Ito T., Tanaka H., Kimura A. Establishment and characterization of a novel imatinib-sensitive chronic myeloid leukemia cell line MYL, and an imatinib-resistant subline MYL-R showing overexpression of Lyn. Eur J Haematol 2007, 78(5):417-431.
90. Gordon PM, Fisher DE. Role for the pro-apoptotic factor BIM in mediating imatinib-induced apoptosis in a c-KIT dependent gastrointestinal stromal tumor cell line. J Biol Chem 2010; [Epub ahead of print].
91. Holtz M.S., Forman S.J., Bhatia R. Nonproliferating CML CD34+ progenitors are resistant to apoptosis induced by a wide range of proapoptotic stimuli. Leukemia 2005, 19(6):1034-1041.
92. Liu Y., Perdreau S.A., Chatterjee P., Wang L., Kuan S.F., Duensing A. Imatinib mesylate induces quiescence in gastrointestinal stromal tumor cells through the CDH1-SKP2-p27Kip1 signaling axis. Cancer Res 2008, 68(21):9015-9023.
93. Parry J.A., Brown M.F., Seneviratne D.S., Duensing S., Duensing A Imatinib mesylate modulates regulators of tumor cell quiescence in gastrointestinal stromal tumor cells. Annual Meeting, Connective Tissue Oncology Society 2009, [abstract 39394].
94. Blay J.Y., Le Cesne A., Ray-Coquard I., Bui B., Duffaud F., Delbaldo C., et al. Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group. J Clin Oncol 2007, 25(9):1107-1113.
95. Milojkovic D., Apperley J. Mechanisms of resistance to imatinib and second-generation tyrosine inhibitors in chronic myeloid leukemia. Clin Cancer Res 2009, 15(24):7519-7527.
96. Sakamoto K, Sakurai S, Kanda T, Sakuma Y, Hishima T, Hironaka M et al. Pleomorphic phenotypes of gastrointestinal stromal tumors at metastatic sites with or without imatinib treatment. Cancer Sci 2010; [Epub ahead of print].
97. Barnes D.J., Melo J.V. Primitive, quiescent and difficult to kill: the role of non-proliferating stem cells in chronic myeloid leukemia. Cell Cycle 2006, 5(24):2862-2866.
98. Holyoake T., Jiang X., Eaves C., Eaves A. Isolation of a highly quiescent subpopulation of primitive leukemic cells in chronic myeloid leukemia. Blood 1999, 94(6):2056-2064.
99. Graham S.M., Jorgensen H.G., Allan E., Pearson C., Alcorn M.J., Richmond L., et al. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood 2002, 99(1):319-325.
100. Holtz M.S., Slovak M.L., Zhang F., Sawyers C.L., Forman S.J., Bhatia R. Imatinib mesylate (STI571) inhibits growth of primitive malignant progenitors in chronic myelogenous leukemia through reversal of abnormally increased proliferation. Blood 2002, 99(10):3792-3800.
101. Goto T., Nishikori M., Arlin Z., Gee T., Kempin S., Burchenal J., et al. Growth characteristics of leukemic and normal hematopoietic cells in Ph' + chronic myelogenous leukemia and effects of intensive treatment. Blood 1982, 59(4):793-808.
102. La Rosee P., Shen L., Stoffregen E.P., Deininger M., Druker B.J. No correlation between the proliferative status of Bcr-Abl positive cell lines and the proapoptotic activity of imatinib mesylate (Gleevec/Glivec). Hematol J 2003, 4(6):413-419.
103. Wang E., Casciano C.N., Clement R.P., Johnson W.W. The farnesyl protein transferase inhibitor SCH66336 is a potent inhibitor of MDR1 product P-glycoprotein. Cancer Res 2001, 61(20):7525-7529.
104. Jordanides N.E., Jorgensen H.G., Holyoake T.L., Mountford J.C. Functional ABCG2 is overexpressed on primary CML CD34+ cells and is inhibited by imatinib mesylate. Blood 2006, 108(4):1370-1373.
105. Goldman J., Gordon M. Why do chronic myelogenous leukemia stem cells survive allogeneic stem cell transplantation or imatinib: does it really matter?. Leuk Lymphoma 2006, 47(1):1-7.
106. Chu S., Xu H., Shah N.P., Snyder D.S., Forman S.J., Sawyers C.L., et al. Detection of BCR-ABL kinase mutations in CD34+ cells from chronic myelogenous leukemia patients in complete cytogenetic remission on imatinib mesylate treatment. Blood 2005, 105(5):2093-2098.
107. Branford S., Rudzki Z., Walsh S., Parkinson I., Grigg A., Szer J., et al. Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood 2003, 102(1):276-283.
108. Jorgensen H.G., Copland M., Allan E.K., Jiang X., Eaves A., Eaves C., et al. Intermittent exposure of primitive quiescent chronic myeloid leukemia cells to granulocyte-colony stimulating factor in vitro promotes their elimination by imatinib mesylate. Clin Cancer Res 2006, 12(2):626-633.
109. Papaetis GS, Syrigos KN. Targeted therapy for gastrointestinal stromal tumors: current status and future perspectives. Cancer Metastasis Rev;29(1):151-70.
110. Van den Abbeele A.D. The lessons of GIST--PET and PET/CT: a new paradigm for imaging. Oncologist 2008, 13(Suppl 2):8-13.
111. Debiec-Rychter M., Cools J., Dumez H., Sciot R., Stul M., Mentens N., et al. Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants. Gastroenterology 2005, 128(2):270-279.
112. Antonescu C.R., Besmer P., Guo T., Arkun K., Hom G., Koryotowski B., et al. Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation. Clin Cancer Res 2005, 11(11):4182-4190.
113. Chen L.L., Trent J.C., Wu E.F., Fuller G.N., Ramdas L., Zhang W., et al. A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors. Cancer Res 2004, 64(17):5913-5919.
114. Tamborini E., Pricl S., Negri T., Lagonigro M.S., Miselli F., Greco A., et al. Functional analyses and molecular modeling of two c-Kit mutations responsible for imatinib secondary resistance in GIST patients. Oncogene 2006, 25(45):6140-6146.
115. Wardelmann E., Thomas N., Merkelbach-Bruse S., Pauls K., Speidel N., Buttner R., et al. Acquired resistance to imatinib in gastrointestinal stromal tumours caused by multiple KIT mutations. Lancet Oncol 2005, 6(4):249-251.
116. Heinrich M.C., Maki R.G., Corless C.L., Antonescu C.R., Harlow A., Griffith D., et al. Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. J Clin Oncol 2008, 26(33):5352-5359.
117. Negri T., Pavan G.M., Virdis E., Greco A., Fermeglia M., Sandri M., et al. T670X KIT mutations in gastrointestinal stromal tumors: making sense of missense. J Natl Cancer Inst 2009, 101(3):194-204.
118. Roberts K.G., Odell A.F., Byrnes E.M., Baleato R.M., Griffith R., Lyons A.B., et al. Resistance to c-KIT kinase inhibitors conferred by V654A mutation. Mol Cancer Ther 2007, 6(3):1159-1166.
119. Foster R., Griffith R., Ferrao P., Ashman L. Molecular basis of the constitutive activity and STI571 resistance of Asp816Val mutant KIT receptor tyrosine kinase. J Mol Graph Model 2004, 23(2):139-152.
120. Gajiwala K.S., Wu J.C., Christensen J., Deshmukh G.D., Diehl W., DiNitto J.P., et al. KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients. Proc Natl Acad Sci USA 2009, 106(5):1542-1547.
121. Lim K.H., Huang M.J., Chen L.T., Wang T.E., Liu C.L., Chang C.S., et al. Molecular analysis of secondary kinase mutations in imatinib-resistant gastrointestinal stromal tumors. Med Oncol 2008, 25(2):207-213.
122. Liegl B., Kepten I., Le C., Zhu M., Demetri G.D., Heinrich M.C., et al. Heterogeneity of kinase inhibitor resistance mechanisms in GIST. J Pathol 2008, 216(1):64-74.
123. Miselli F.C., Casieri P., Negri T., Orsenigo M., Lagonigro M.S., Gronchi A., et al. c-Kit/PDGFRA gene status alterations possibly related to primary imatinib resistance in gastrointestinal stromal tumors. Clin Cancer Res 2007, 13(8):2369-2377.
124. Heinrich M.C., Corless C.L., Blanke C.D., Demetri G.D., Joensuu H., Roberts P.J., et al. Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J Clin Oncol 2006, 24(29):4764-4774.
125. Judson I., Ma P., Peng B., Verweij J., Racine A., di Paola E.D., et al. Imatinib pharmacokinetics in patients with gastrointestinal stromal tumour: a retrospective population pharmacokinetic study over time. EORTC Soft Tissue and Bone Sarcoma Group. Cancer Chemother Pharmacol 2005, 55(4):379-386.
126. Delbaldo C., Chatelut E., Re M., Deroussent A., Seronie-Vivien S., Jambu A., et al. Pharmacokinetic-pharmacodynamic relationships of imatinib and its main metabolite in patients with advanced gastrointestinal stromal tumors. Clin Cancer Res 2006, 12(20 Pt 1):6073-6078.
127. Rock E.P., Goodman V., Jiang J.X., Mahjoob K., Verbois S.L., Morse D., et al. Food and drug administration drug approval summary: sunitinib malate for the treatment of gastrointestinal stromal tumor and advanced renal cell carcinoma. Oncologist 2007, 12(1):107-113.
128. Goodman V.L., Rock E.P., Dagher R., Ramchandani R.P., Abraham S., Gobburu J.V., et al. Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma. Clin Cancer Res 2007, 13(5):1367-1373.
129. Faivre S., Delbaldo C., Vera K., Robert C., Lozahic S., Lassau N., et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 2006, 24(1):25-35.
130. Demetri G.D., van Oosterom A.T., Garrett C.R., Blackstein M.E., Shah M.H., Verweij J., et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 2006, 368(9544):1329-1338.
131. Liegl B., Fletcher J.A., Corless C.L., Fletcher C.D., Raut C.P., Donsky R., et al. Correlation between KIT mutations and sunitinib (SU) resistance in GIST. ASCO Gastrointestinal Cancers Symposium 2008, [abstract 92].
132. Prenen H., Guetens G., de Boeck G., Debiec-Rychter M., Manley P., Schoffski P., et al. Cellular uptake of the tyrosine kinase inhibitors imatinib and AMN107 in gastrointestinal stromal tumor cell lines. Pharmacology 2006, 77(1):11-16.
133. Montemurro M., Schoffski P., Reichardt P., Gelderblom H., Schutte J., Hartmann J.T., et al. Nilotinib in the treatment of advanced gastrointestinal stromal tumours resistant to both imatinib and sunitinib. Eur J Cancer 2009, 45(13):2293-2297.
134. Wiebe L.K.K., Maki R.G., D'Adamo D.R., Chow W.A., Wade J.L., Agamah E., et al. Activity of sorafenib (SOR) in patients (pts) with imatinib (IM) and sunitinib (SU)-resistant (RES) gastrointestinal stromal tumors (GIST): a phase II trial of the University of Chicago phase II consortium. J Clin Oncol 2008, 26:10502.
135. Dewaele B., Wasag B., Cools J., Sciot R., Prenen H., Vandenberghe P., et al. Activity of dasatinib, a dual SRC/ABL kinase inhibitor, and IPI-504, a heat shock protein 90 inhibitor, against gastrointestinal stromal tumor-associated PDGFRAD842V mutation. Clin Cancer Res 2008, 14(18):5749-5758.
136. Bauer S., Yu L.K., Demetri G.D., Fletcher J.A. Heat shock protein 90 inhibition in imatinib-resistant gastrointestinal stromal tumor. Cancer Res 2006, 66(18):9153-9161.
137. Fumo G., Akin C., Metcalfe D.D., Neckers L. 17-Allylamino-17-demethoxygeldanamycin (17-AAG) is effective in down-regulating mutated, constitutively activated KIT protein in human mast cells. Blood 2004, 103(3):1078-1084.
138. Demetri G.D., Le Censne A., von Mehren M., Chmielowski B., Bauer S., Chow W.A., Rodenas E., et al. Final results from a phase III study of IPI-504 (retaspimycin hydrochloride) versus placebo in patients (pts) with gastrointestinal stromal tumors (GIST) following failure of kinase inhibitor therapies. ASCO Gastrointestinal Cancers Symposium 2010, [abstract 64].
139. Gunaratnam M., Swank S., Haider S.M., Galesa K., Reszka A.P., Beltran M., et al. Targeting human gastrointestinal stromal tumor cells with a quadruplex-binding small molecule. J Med Chem 2009, 52(12):3774-3783.
140. Michor F., Hughes T.P., Iwasa Y., Branford S., Shah N.P., Sawyers C.L., et al. Dynamics of chronic myeloid leukaemia. Nature 2005, 435(7046):1267-1270.
141. Desai J., Shankar S., Heinrich M.C., Fletcher J.A., Fletcher C.D., Manola J., et al. Clonal evolution of resistance to imatinib in patients with metastatic gastrointestinal stromal tumors. Clin Cancer Res 2007, 13(18 Pt 1):5398-5405.
142. Wardelmann E., Merkelbach-Bruse S., Pauls K., Thomas N., Schildhaus H.U., Heinicke T., et al. Polyclonal evolution of multiple secondary KIT mutations in gastrointestinal stromal tumors under treatment with imatinib mesylate. Clin Cancer Res 2006, 12(6):1743-1749.
143. Andersson J., Sihto H., Meis-Kindblom J.M., Joensuu H., Nupponen N., Kindblom L.G. NF1-associated gastrointestinal stromal tumors have unique clinical. phenotypic, and genotypic characteristics. Am J Surg Pathol 2005, 29(9):1170-1176.
144. Maertens O., Prenen H., Debiec-Rychter M., Wozniak A., Sciot R., Pauwels P., et al. Molecular pathogenesis of multiple gastrointestinal stromal tumors in NF1 patients. Hum Mol Genet 2006, 15(6):1015-1023.
145. Miettinen M., Fetsch J.F., Sobin L.H., Lasota J. Gastrointestinal stromal tumors in patients with neurofibromatosis 1: a clinicopathologic and molecular genetic study of 45 cases. Am J Surg Pathol 2006, 30(1):90-96.
146. Muhlenberg T., Zhang Y., Wagner A.J., Grabellus F., Bradner J., Taeger G., et al. Inhibitors of deacetylases suppress oncogenic KIT signaling, acetylate HSP90, and induce apoptosis in gastrointestinal stromal tumors. Cancer Res 2009, 69(17):6941-6950.
147. Kovacs J.J., Murphy P.J., Gaillard S., Zhao X., Wu J.T., Nicchitta C.V., et al. HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor. Mol Cell 2005, 18(5):601-607.
148. Bali P., Pranpat M., Bradner J., Balasis M., Fiskus W., Guo F., et al. Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors. J Biol Chem 2005, 280(29):26729-26734.
149. Floris G., Debiec-Rychter M., Sciot R., Stefan C., Fieuws S., Machiels K., et al. High efficacy of panobinostat towards human gastrointestinal stromal tumors in a xenograft mouse model. Clin Cancer Res 2009, 15(12):4066-4076.
150. Bauer S, Parry JA, Muhlenberg T, Brown MF, Seneviratne D, Chatterjee P et al. Proapoptotic activity of bortezomib in gastrointestinal stromal tumor cells. Cancer Res 2010;70(1):150-9.